Indivior (NASDAQ:INDV) Releases Earnings Results, Beats Expectations By $0.26 EPS

Posted by on Aug 4th, 2026

Indivior (NASDAQ:INDV – Get Free Report) released its quarterly earnings data on Monday. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.26, Zacks reports. The firm had revenue of $343.00 million during the quarter, compared to the consensus estimate of $307.55 million. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.

Here are the key takeaways from Indivior’s conference call:

  • Positive Sentiment: The proposed all-stock merger would create a diversified CNS company with approximately $2.2 billion in pro forma revenue across addiction, ADHD, depression, and Parkinson’s disease, supported by 11 marketed medicines and five key growth products.
  • Positive Sentiment: Management expects at least $125 million in annual cost synergies within the first 12 months after closing, primarily from G&A redundancies and operational efficiencies; pro forma adjusted EBITDA is estimated at $888 million, including the synergies.
  • Positive Sentiment: SUBLOCADE, expected to represent roughly 44% of combined revenue, is described as the primary growth driver, with record new-patient starts, approximately 76% market share, and a long patent and manufacturing-complexity runway extending potentially into 2042–2044.
  • Positive Sentiment: The combined balance sheet is expected to provide greater capacity for business development, with management targeting primarily mid- to late-stage CNS, psychiatry, neurology, and women’s-health assets while maintaining disciplined leverage of roughly 2.5x to 3.0x adjusted EBITDA.
  • Negative Sentiment: The transaction remains subject to shareholder and regulatory approvals and customary closing conditions, with closing expected in the fourth quarter of 2026; management provided no formal forward earnings guidance beyond the pro forma figures.

Indivior Stock Performance

Indivior stock opened at $37.37 on Tuesday. Indivior has a 1 year low of $20.67 and a 1 year high of $42.81. The firm has a 50 day moving average price of $39.17 and a 200 day moving average price of $35.51. The company has a market cap of $4.56 billion, a price-to-earnings ratio of 19.16 and a beta of 0.86.

Insider Buying and Selling

In other news, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. The trade was a 11.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.74% of the company’s stock.

Institutional Trading of Indivior

A number of institutional investors and hedge funds have recently bought and sold shares of INDV. Goldman Sachs Group Inc. raised its stake in shares of Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the period. Jane Street Group LLC grew its position in shares of Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Indivior by 669.1% during the second quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after purchasing an additional 340,498 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Indivior in the second quarter worth $207,000. Finally, Walleye Capital LLC acquired a new stake in shares of Indivior in the second quarter valued at approximately $594,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on INDV shares. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 24th. Finally, Barclays began coverage on shares of Indivior in a research note on Thursday, June 18th. They issued an “overweight” rating and a $46.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Indivior has a consensus rating of “Moderate Buy” and an average price target of $43.67.

View Our Latest Stock Analysis on INDV

Key Stories Impacting Indivior

Here are the key news stories impacting Indivior this week:

  • Positive Sentiment: Q2 results exceeded expectations: Indivior reported adjusted earnings of $1.15 per share, above analyst estimates of $0.89-$0.97, while revenue rose 14% year over year to $343 million, surpassing the $307.6 million consensus. Indivior Q2 Earnings and Revenues Beat Estimates
  • Positive Sentiment: Record performance and raised guidance: SUBLOCADE revenue reached a record $253 million, up 21% year over year. Adjusted EBITDA climbed 111% to $186 million, and the company posted record GAAP net income of $122 million. Indivior raised its full-year 2026 revenue outlook to $1.3 billion-$1.4 billion, broadly in line with or above consensus expectations. Indivior Reports Second-Quarter Results and Raises Guidance
  • Positive Sentiment: Share repurchases supported per-share value: Indivior bought back approximately 4.7 million shares for $175 million during the quarter, potentially improving future earnings per share.
  • Neutral Sentiment: Merger creates potential scale: Indivior and Supernus agreed to an all-stock merger that is expected to form a neuroscience-focused company with approximately $2.2 billion in annual revenue, complementary neurological, psychiatric and addiction treatments, and anticipated cost synergies. Indivior shareholders would own about 56.5% of the combined company. Supernus and Indivior Merger
  • Negative Sentiment: Deal scrutiny is weighing on sentiment: Investor-rights law firms announced investigations into whether Indivior shareholders are receiving a fair price and whether the merger process disclosed sufficient information. The inquiries do not establish wrongdoing, but they add legal and closing-risk concerns to the all-stock transaction. Shareholder Investigation of Indivior

Indivior Company Profile

(Get Free Report)

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

Featured Stories

Earnings History for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.